American Society of Gene & Cell Therapy and Orphan Therapeutics Accelerator partner to advance and commercialize promising rare disease treatments
The ASGCT and OTXL partnership, CGTxchange, aims to facilitate the development and commercialization of deprioritized cell and gene therapies for ultra-rare diseases. The joint venture leverages an AI-based platform to match CGTs with prospective investors or partners.